Haemonetics (HAE)


Market Price (11/19/2026): $122.83 | Market Cap: $5.6 BilSector: Health Care | Industry: Health Care Supplies

Haemonetics (HAE)


Market Price (11/19/2026): $122.83
Market Cap: $5.6 Bil
Sector: Health Care
Industry: Health Care Supplies

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 4: up 5.9% in one day (S&P 500 up 1.7%)
The stock rose without company news, as the market also gained significantly on a "Blue Wave" sentiment.

Up 143.9% from its May 11 low to Nov 4, down 3.6% since (S&P 500 up 4.2%)
The stock gained significantly over the period, driven by an expanding plasma deal that opened doors to more revenue. The largest daily rise on October 8 occurred after a deal to expand plasma collection equipment use.

Nov 6: down 3.4% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock declined following Haemonetics' fiscal Q2 2027 financial results. Reported revenue increased 9% and diluted EPS rose 23% year-over-year, surpassing estimates, while the market gained.

Show more
Prices as of 11/18/2026

Nov 4: up 5.9% in one day (S&P 500 up 1.7%)
The stock rose without company news, as the market also gained significantly on a "Blue Wave" sentiment.

Up 143.9% from its May 11 low to Nov 4, down 3.6% since (S&P 500 up 4.2%)
The stock gained significantly over the period, driven by an expanding plasma deal that opened doors to more revenue. The largest daily rise on October 8 occurred after a deal to expand plasma collection equipment use.

Nov 6: down 3.4% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock declined following Haemonetics' fiscal Q2 2027 financial results. Reported revenue increased 9% and diluted EPS rose 23% year-over-year, surpassing estimates, while the market gained.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 43.6% change in HAE stock from 7/31/2026 to 11/18/2026 was primarily driven by a 32.4% change in the company's P/E Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)85.54122.8643.6%
Change Contribution By: 
Total Revenues ($ Mil)1,3341,3823.6%
Net Income Margin (%)7.3%7.5%3.0%
P/E Multiple40.653.832.4%
Shares Outstanding (Mil)46461.6%
Cumulative Contribution43.6%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
HAE43.6% 
Market (SPY)-2.0%3.2%
Sector (XLV)11.9%19.9%

Fundamental Drivers

The 104.5% change in HAE stock from 4/30/2026 to 11/18/2026 was primarily driven by a 235.7% change in the company's P/E Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)60.09122.86104.5%
Change Contribution By: 
Total Revenues ($ Mil)1,3181,3824.9%
Net Income Margin (%)13.3%7.5%-43.5%
P/E Multiple16.053.8235.7%
Shares Outstanding (Mil)47462.8%
Cumulative Contribution104.5%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
HAE104.5% 
Market (SPY)2.1%2.4%
Sector (XLV)25.1%26.1%

Fundamental Drivers

The 145.7% change in HAE stock from 10/31/2025 to 11/18/2026 was primarily driven by a 265.2% change in the company's P/E Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)50.01122.86145.7%
Change Contribution By: 
Total Revenues ($ Mil)1,3461,3822.7%
Net Income Margin (%)12.1%7.5%-38.1%
P/E Multiple14.753.8265.2%
Shares Outstanding (Mil)48465.7%
Cumulative Contribution145.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
HAE145.7% 
Market (SPY)8.2%2.2%
Sector (XLV)27.7%20.0%

Fundamental Drivers

The 44.2% change in HAE stock from 10/31/2023 to 11/18/2026 was primarily driven by a 70.6% change in the company's P/E Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)85.23122.8644.2%
Change Contribution By: 
Total Revenues ($ Mil)1,2191,38213.5%
Net Income Margin (%)11.2%7.5%-32.9%
P/E Multiple31.553.870.6%
Shares Outstanding (Mil)514611.1%
Cumulative Contribution44.2%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
HAE44.2% 
Market (SPY)81.1%19.7%
Sector (XLV)52.9%27.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HAE Return-55%48%9%-9%3%53%3%
Peers Return9%-25%-12%4%1%34%-1%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
HAE Win Rate42%67%58%42%33%73% 
Peers Win Rate45%38%42%48%47%62% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
HAE Max Drawdown-64%-23%-18%-27%-40%-38% 
Peers Max Drawdown-17%-38%-34%-21%-34%-25% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ICUI, LIVN, BAX, BDX, MDT. See HAE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventHAES&P 500
2025 US Tariff Shock
  % Loss-12.0%-18.8%
  % Gain to Breakeven13.6%23.1%
  Time to Breakeven21 days79 days
2024 Yen Carry Trade Unwind
  % Loss-16.0%-7.8%
  % Gain to Breakeven19.0%8.5%
  Time to Breakeven86 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-12.2%-9.5%
  % Gain to Breakeven13.9%10.5%
  Time to Breakeven153 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-20.0%-24.5%
  % Gain to Breakeven25.0%32.4%
  Time to Breakeven13 days427 days
2020 COVID-19 Crash
  % Loss-38.3%-33.7%
  % Gain to Breakeven62.0%50.9%
  Time to Breakeven294 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-19.2%-19.2%
  % Gain to Breakeven23.8%23.8%
  Time to Breakeven175 days105 days

Compare to ICUI, LIVN, BAX, BDX, MDT

In The Past

Haemonetics's stock fell -12.0% during the 2025 US Tariff Shock. Such a loss loss requires a 13.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventHAES&P 500
2020 COVID-19 Crash
  % Loss-38.3%-33.7%
  % Gain to Breakeven62.0%50.9%
  Time to Breakeven294 days140 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-24.6%-12.2%
  % Gain to Breakeven32.6%13.9%
  Time to Breakeven309 days62 days
2008-2009 Global Financial Crisis
  % Loss-21.0%-53.4%
  % Gain to Breakeven26.7%114.4%
  Time to Breakeven101 days1085 days

Compare to ICUI, LIVN, BAX, BDX, MDT

In The Past

Haemonetics's stock fell -12.0% during the 2025 US Tariff Shock. Such a loss loss requires a 13.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Haemonetics (HAE)

```html

Haemonetics Corporation (HAE) is a global healthcare company that develops and provides a range of medical products and solutions primarily focused on blood and plasma management. The company's mission is to help healthcare professionals and organizations efficiently collect, process, and manage blood components and plasma, while also offering crucial diagnostic tools to enhance patient care and operational efficiency.

The company operates through three main segments. In its Plasma segment, Haemonetics offers automated plasma collection devices like NexSys PCS, along with associated disposables and integrated software platforms such as NexLynk DMS. These solutions enable plasma centers to streamline donor management, optimize operations, and manage their supply chain effectively. The Blood Center segment provides automated apheresis equipment (e.g., MCS brand) for collecting specific blood components, manual whole blood collection sets, and sophisticated software systems like SafeTrace Tx to manage donations, track blood units, and support donor recruitment and retention for blood banks.

Haemonetics' Hospital segment delivers critical products for patient care within hospital settings. This includes the TEG diagnostic systems, which allow clinicians to quickly assess a patient's coagulation status at the point-of-care or in the lab, supported by TEG Manager software for remote access. Additionally, the company offers the Cell Saver Elite+ for autologous blood recovery during surgeries and the BloodTrack suite, a comprehensive set of software and hardware solutions designed for advanced blood management and safe bedside transfusions. These hospital products serve clinicians, surgeons, and hospital blood banks, contributing to improved patient outcomes and operational efficiency in surgical, critical care, and general hospital environments.

```

AI Analysis | Feedback

It's like BD (Becton, Dickinson and Company) for specialized blood and plasma collection and management solutions.

Think of it as a highly focused Thermo Fisher Scientific for blood and plasma processing, diagnostics, and patient care.

AI Analysis | Feedback

  • NexSys PCS and PCS2: Automated plasmapheresis equipment and associated disposables for plasma collection.
  • NexLynk DMS: An integrated information technology platform for managing plasma donors, operations, and supply chain.
  • MCS brand apheresis equipment: Automated systems for collecting specific blood components from donors.
  • Disposable whole blood collection and component storage sets: Products used for manual whole blood collection and storing blood components.
  • SafeTrace Tx and El-Dorado Donor: Management systems for blood donations and blood units.
  • TEG diagnostic systems: Point-of-care and laboratory systems that assess a patient's coagulation status.
  • Cell Saver Elite +: An autologous blood recovery system used in various surgical procedures.
  • BloodTrack: A suite of solutions combining software and hardware for blood management and bedside transfusion.

AI Analysis | Feedback

Haemonetics (HAE) primarily sells its products and solutions to other companies and organizations, rather than directly to individuals. The provided company description does not list the names of specific customer companies or their symbols.

However, based on the description of its three segments, Haemonetics' major customers fall into the following categories of organizational entities:

  1. Plasma Collection Companies/Centers: These customers utilize Haemonetics' automated plasma collection devices, related disposables, software, and IT platforms (e.g., NexSys PCS, NexLynk DMS) to manage donors, operations, and supply chains for plasma collection.
  2. Blood Centers and Blood Banks: Customers in this category use products such as automated blood component collection systems (e.g., MCS brand apheresis equipment), disposable whole blood collection and storage sets, and blood unit management software (e.g., SafeTrace Tx, Hemasphere) for donor management and blood processing.
  3. Hospitals and Clinical Laboratories: This segment's customers include hospitals and their associated laboratories, which use products like TEG diagnostic systems for coagulation assessment, Cell Saver Elite + for autologous blood recovery during surgery, and BloodTrack solutions for blood management and bedside transfusions.

AI Analysis | Feedback

null

AI Analysis | Feedback

Christopher Simon, President and Chief Executive Officer

Christopher Simon was appointed President and Chief Executive Officer of Haemonetics in May 2016. He brings over 30 years of experience in healthcare. Prior to joining Haemonetics, he served as a Senior Partner at McKinsey & Company, where he led the Global Medical Products Practice. Earlier in his career, he held commercial and operating roles at Baxter Healthcare Corporation and served as a U.S. Army Infantry Officer. Mr. Simon holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

James C. D'Arecca, Executive Vice President, Chief Financial Officer

James C. D'Arecca joined Haemonetics as Executive Vice President, Chief Financial Officer in April 2022. He has nearly 30 years of experience in finance leadership and strategy. Before Haemonetics, Mr. D'Arecca was Chief Financial Officer of TherapeuticsMD, a women's healthcare company, from June 2020 to April 2022. He previously served as Senior Vice President and Chief Accounting Officer at Allergan plc (formerly Actavis plc) for nearly seven years until its merger with AbbVie Inc. in May 2020. His career also includes roles as Chief Accounting Officer at Bausch & Lomb and finance and business development positions at Merck & Co., Inc. and Schering-Plough. He began his career at PricewaterhouseCoopers, focusing on pharmaceuticals, medical devices, and consumer products. Mr. D'Arecca is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Rutgers University and an MBA from Columbia University.

Michelle L. Basil, Executive Vice President, General Counsel

Michelle L. Basil serves as the Executive Vice President, General Counsel of Haemonetics.

Frank W. Chan, Ph.D., Executive Vice President, Chief Operating Officer

Frank W. Chan, Ph.D. joined Haemonetics as Executive Vice President, Chief Operating Officer in April 2025. He has over 25 years of experience in medical device and healthcare technology leadership, including delivering innovative solutions to market and leading business transformation. Prior to Haemonetics, he was President of Acute Care & Monitoring at Medtronic plc and held various roles at Covidien plc (acquired by Medtronic) and DePuy Orthopaedics, Inc. (a Johnson & Johnson company).

Roy Galvin, Executive Vice President, Chief Commercial Officer

Roy Galvin was appointed Executive Vice President, Chief Commercial Officer in March 2025. He originally joined Haemonetics in 2022 as President, Global Plasma and Blood Center. In his expanded role, he is responsible for the company's Global Hospital business, as well as Global Plasma and Blood Center, overseeing all commercialization initiatives.

AI Analysis | Feedback

The key risks to Haemonetics' business are:

  1. Dependence on Plasma and Blood Donation Volumes and Regulatory Changes: A significant portion of Haemonetics' revenue is derived from its Plasma and Blood Center segments, which are directly reliant on the volume of plasma and whole blood donations. Any factors that negatively impact donor availability, such as public health crises, changes in donor eligibility criteria, or shifts in societal attitudes towards donation, could reduce demand for their collection devices, disposables, and donor management systems. Additionally, changes in regulatory policies regarding plasma collection, blood safety, or donor compensation could significantly affect these core business segments.

  2. Intense Competition and Rapid Technological Advancements: Haemonetics operates in highly competitive markets across its Plasma, Blood Center, and Hospital segments. The medical device and healthcare IT industries are characterized by continuous innovation and evolving technologies. Competitors may develop more advanced, efficient, or cost-effective collection systems, diagnostic tools, or blood management software. The company's ability to maintain and grow its market share depends on its capacity for ongoing research and development, successful product innovation, and effective differentiation from competitors.

  3. Supply Chain Risks for Critical Disposables: Many of Haemonetics' products, including those for plasma collection, blood component separation, and surgical blood recovery (e.g., Cell Saver Elite+), utilize proprietary disposable components. Disruptions in the supply chain for these critical disposables, such as raw material shortages, manufacturing delays, or geopolitical events, could significantly impact the company's ability to supply its customers, fulfill orders, and generate recurring revenue. This reliance on a steady and reliable supply of disposables makes the company vulnerable to various supply chain challenges.

AI Analysis | Feedback

null

AI Analysis | Feedback

Haemonetics Corporation (HAE) operates in several key medical technology markets, providing products and solutions across plasma, blood center, and hospital segments. The addressable markets for its main products and services include:

  • Plasma Collection Devices and Related Disposables (e.g., NexSys PCS, PCS2 plasmapheresis equipment): These products fall under the broader Apheresis Equipment Market. The global apheresis equipment market size was valued at approximately USD 3.51 billion in 2025 and is projected to increase to about USD 8.39 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 9.11% from 2026 to 2035. North America held the largest share of this global market, accounting for 35% in 2025.

  • Automated Blood Component and Manual Whole Blood Collection Systems (e.g., MCS brand apheresis equipment, disposable whole blood collection sets): These products are part of the global Blood Collection Devices Market. This market was valued at USD 9.4 billion in 2025 and is projected to grow to USD 18.07 billion by 2034, at a CAGR of 7.53%. North America accounts for approximately 35% of the Blood Collection Devices Market.

  • TEG Diagnostic Systems: These are key components of the Thromboelastography Analyzer Market. The global thromboelastography analyzer market size was valued at USD 383 million in 2024 and is projected to reach USD 729 million by 2032, with a CAGR of 9.9%. North America dominates this market, holding a 37% share.

  • Cell Saver Elite+ (Autologous Blood Recovery System): This product is part of the Autotransfusion Systems Market. The global autotransfusion systems market size was over USD 534.6 million in 2025 and is estimated to reach USD 872.9 million by the end of 2035, growing at a CAGR of 5.6% during the forecast timeline. North America is projected to be the largest regional market, holding a 34.6% share by 2035.

  • BloodTrack (Blood Management and Bedside Transfusion Solutions): This falls under the Blood Management Software Market. This market was valued at USD 1.23 billion in 2025 and is estimated to grow to USD 2.05 billion by 2031, at a CAGR of 8.84%. North America accounted for 38.10% of the market revenue in 2025.

AI Analysis | Feedback

Haemonetics (HAE) anticipates several key drivers to fuel its revenue growth over the next two to three years:

  1. Plasma Segment Expansion and Innovation: Growth in the Plasma segment is expected to be a primary driver, propelled by the continued adoption and innovation of its NexSys PCS system, particularly with the proprietary Persona Technology. This technology is designed to enhance plasma yield, improve operational efficiency in collection centers, and elevate the donor experience. The company foresees sustained strong performance in its Plasma business, supported by increasing global demand for plasma collections.
  2. Hospital Segment Strength, particularly Blood Management Technologies: The Hospital business is projected to maintain robust growth, especially within its Blood Management Technologies portfolio. This includes the strong performance of TEG diagnostic systems and the increasing adoption of the heparinase neutralization cartridge in hemostasis management. Additionally, the VASCADE closure devices, including newer introductions like VASCADE MVP XL expanding into electrophysiology, are expected to continue contributing to revenue expansion within this segment.
  3. New Product Launches and Research & Development: Haemonetics is committed to significant investment in research and development to expand its product offerings. Key anticipated launches that are expected to drive future revenue include an advanced whole blood automation system, designed to streamline blood collection and processing, and the U.S. launch of PerQseal Elite. The company's focus on developing next-generation technologies and AI-driven analytics platforms underscores its innovation-led growth strategy.
  4. Geographical Market Expansion: The company is strategically targeting high-growth emerging markets for expansion, with a particular focus on the Asia-Pacific (APAC) region. This geographical diversification is a key initiative to broaden its customer base and generate additional revenue streams over the coming years.

AI Analysis | Feedback

Share Repurchases

  • In April 2025, Haemonetics' Board of Directors authorized a new share repurchase program of up to $500 million of common stock over the next three years to offset the dilutive impact of employee equity grants.
  • During fiscal year 2025, Haemonetics completed its prior $300 million share repurchase program, which included an accelerated share repurchase agreement for $150 million that resulted in the repurchase of approximately 2.4 million shares.
  • As of November 2025, the company completed a $75 million buyback, repurchasing 1,430,579 shares (approximately 2.97% of outstanding stock) under the May 2025 authorization.

Share Issuance

  • In May 2024, Haemonetics announced its intention to offer $525 million aggregate principal amount of Convertible Senior Notes due 2029 in a private offering, with an option for initial purchasers to acquire up to an additional $75 million. The proceeds are intended for capped call transactions, working capital, and general corporate purposes, including debt repayment.
  • In March 2021, the company priced an offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due 2026, which was an increase from the previously announced $425 million. An option for an additional $65 million principal amount was also granted.
  • The total net proceeds from the sale of the 2026 Convertible Senior Notes were approximately $486.7 million.

Outbound Investments

  • In January 2026, Haemonetics acquired Vivasure Medical Limited in a transaction valued up to €185 million (approximately $215 million) upon the completion of certain milestones. Haemonetics had previously made a strategic investment in Vivasure Medical in 2022, which included an option to acquire the company.
  • In December 2023, Haemonetics completed the acquisition of OpSens Inc., a cardiology-focused medical device company, for approximately $255 million in an all-cash transaction. This acquisition expanded Haemonetics' presence in the interventional cardiology market.
  • In April 2024, the company acquired Attune Medical for $160 million, adding an Esophageal Protection product line and expanding its Hospital segment.

Capital Expenditures

  • Haemonetics' capital expenditures were $39.278 million in fiscal year 2025 and $38.125 million in fiscal year 2024.
  • The company's capital allocation strategy prioritizes funding planned internal investments to support growth.
  • Expected capital expenditures are estimated at $40 million for fiscal 2026, $41 million for fiscal 2027, and $42 million for fiscal 2028.

Better Bets vs. Haemonetics (HAE)

Peer Outperformance in Health Care Supplies

HAE has outperformed 90% of its 10 Health Care Supplies peers over 5Y. Health Care Supplies ranks 6th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Health Care Supplies constituents that HAE has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
80%
of 10 industry peers · 65.1% return
3Y
80%
of 10 industry peers · 47.7% return
5Y
90%
of 10 industry peers · 119.6% return
No Health Care Supplies peer with a comparable growth profile has beaten HAE by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Supplies is HAE's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies ← 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HAEICUILIVNBAXBDXMDTMedian
NameHaemonet.ICU Medi.LivaNova Baxter I.Becton D.Medtronic 
Mkt Price122.83178.6794.4426.16216.09100.66111.75
Mkt Cap5.64.55.213.559.4128.89.6
Rev LTM1,3822,1831,50711,61123,25037,5416,897
Op Inc LTM2531751622643,3447,147259
FCF LTM2982021291,1342,5096,132716
FCF 3Y Avg2011411436702,7685,527436
CFO LTM3452792381,6403,2628,035992
CFO 3Y Avg2402312161,1503,4877,360695

Growth & Margins

HAEICUILIVNBAXBDXMDTMedian
NameHaemonet.ICU Medi.LivaNova Baxter I.Becton D.Medtronic 
Rev Chg LTM4.1%-5.9%11.7%5.3%17.4%9.8%7.6%
Rev Chg 3Y Avg3.8%-0.9%10.5%8.5%7.1%6.0%6.6%
Rev Chg Q9.3%4.4%9.9%5.0%5.4%13.7%7.4%
QoQ Delta Rev Chg LTM2.3%1.1%2.4%1.2%1.1%3.2%1.7%
Op Inc Chg LTM10.8%35.7%-16.4%-35.8%26.1%7.5%9.2%
Op Inc Chg 3Y Avg15.1%63.9%90.3%919.0%10.7%6.3%39.5%
Op Mgn LTM18.3%8.0%10.7%2.3%14.4%19.0%12.6%
Op Mgn 3Y Avg16.2%5.2%10.9%4.4%13.5%18.5%12.2%
QoQ Delta Op Mgn LTM0.2%1.4%-2.0%0.4%-0.5%0.3%0.2%
CFO/Rev LTM25.0%12.8%15.8%14.1%14.0%21.4%15.0%
CFO/Rev 3Y Avg17.7%10.2%15.7%10.3%16.8%21.2%16.2%
FCF/Rev LTM21.6%9.2%8.6%9.8%10.8%16.3%10.3%
FCF/Rev 3Y Avg14.8%6.2%10.5%6.0%13.3%15.9%11.9%

Valuation

HAEICUILIVNBAXBDXMDTMedian
NameHaemonet.ICU Medi.LivaNova Baxter I.Becton D.Medtronic 
Mkt Cap5.64.55.213.559.4128.89.6
P/S4.02.03.51.22.63.43.0
P/Op Inc22.125.532.151.217.818.023.8
P/EBIT31.638.134.2121.823.317.632.9
P/E53.874.126.5-18.763.124.640.2
P/CFO16.216.021.98.218.216.016.1
Total Yield1.9%1.4%3.8%-4.6%3.6%6.9%2.7%
Dividend Yield0.0%0.0%0.0%0.8%2.0%2.8%0.4%
FCF Yield 3Y Avg6.2%3.6%4.5%4.8%4.8%5.3%4.8%
D/E0.20.30.10.70.30.20.2
Net D/E0.20.2-0.00.50.30.20.2

Returns

HAEICUILIVNBAXBDXMDTMedian
NameHaemonet.ICU Medi.LivaNova Baxter I.Becton D.Medtronic 
1M Rtn3.5%10.8%20.9%4.7%13.3%8.5%9.7%
3M Rtn13.3%-4.6%16.8%-1.8%15.9%7.8%10.6%
6M Rtn106.2%38.2%28.1%39.5%49.0%31.0%38.8%
12M Rtn65.1%33.3%75.2%44.4%46.5%3.2%45.4%
3Y Rtn47.6%108.8%101.9%-22.0%25.3%48.5%48.1%
1M Excs Rtn7.7%14.8%22.3%10.5%15.3%10.2%12.7%
3M Excs Rtn16.4%0.8%23.7%2.0%18.8%12.9%14.7%
6M Excs Rtn106.4%38.4%28.3%39.7%49.2%31.3%39.0%
12M Excs Rtn54.1%21.7%64.9%36.3%36.4%-3.1%36.4%
3Y Excs Rtn-26.4%49.6%34.1%-86.1%-44.2%-14.0%-20.2%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20262025202420232022
Hospital588564456382322
Plasma524535570500352
Blood Center221261283287295
Effect of exchange rates    4
Service    21
Total1,3341,3611,3091,169993


Operating Income by Segment
$ Mil20262025202420232022
Plasma185185182125183
Hospital104895229130
Blood Center50534264137
Remeasurement of contingent consideration2230  
Restructuring and restructuring related costs-3-21-24-12 
Other-82-15-14 
Acquisition, integration and divestiture related costs-14-23-110 
Digital transformation costs-22-20-16-50
Amortization of acquired assets-50-63-35-33-47
Impairment of intangible assets-87-2-10 0
Contingent Consideration   0 
Amortization of fair value inventory step-up    0
Corporate expenses    -281
Effect of exchange rates    19
Gains on divestiture and sale of assets    10
Integration and transaction costs    -22
Litigation-related charges    -1
Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) costs    -11
Restructuring costs    -4
Restructuring related costs    -25
Write downs of certain in-process assets and PCS2 related charges    -6
Total15722216515681


Price Behavior

Price Behavior
Market Price$122.86 
Market Cap ($ Bil)5.6 
First Trading Date05/10/1991 
Distance from 52W High-3.6% 
   50 Days200 Days
DMA Price$114.43$82.10
DMA Trendupup
Distance from DMA7.4%49.6%
 3M1YR
Volatility42.5%41.0%
Downside Capture-56.0712.91
Upside Capture-4.0668.06
Correlation (S&P 500)8.8%8.5%
HAE Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta-0.44-0.02-0.34-0.11-0.000.55
Up Beta1.621.11-0.26-1.37-0.480.57
Down Beta2.591.290.070.08-0.400.30
Up Capture-54%0%40%105%79%37%
Bmk +ve Days12182862130427
Stock +ve Days9202964131376
Down Capture-266%-132%-194%-109%-34%88%
Bmk -ve Days10253664121325
Stock -ve Days12223461119371

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HAE
HAE65.6%41.0%1.32-
Sector ETF (XLV)21.5%17.0%0.9624.2%
Equity (SPY)10.9%13.8%0.498.7%
Gold (GLD)-8.2%29.0%-0.30-3.1%
Commodities (DBC)28.8%21.5%1.07-12.0%
Real Estate (VNQ)11.2%14.2%0.5019.2%
Bitcoin (BTCUSD)-29.6%43.7%-0.69-3.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HAE
HAE14.9%40.4%0.45-
Sector ETF (XLV)8.0%15.4%0.3332.4%
Equity (SPY)11.0%17.3%0.4630.1%
Gold (GLD)14.5%19.2%0.601.1%
Commodities (DBC)6.8%19.6%0.242.3%
Real Estate (VNQ)1.1%19.0%-0.0530.1%
Bitcoin (BTCUSD)-0.0%51.4%0.1812.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HAE
HAE12.5%40.6%0.43-
Sector ETF (XLV)12.1%16.8%0.5933.7%
Equity (SPY)14.9%18.0%0.7035.4%
Gold (GLD)10.9%16.6%0.530.6%
Commodities (DBC)7.2%18.2%0.3110.1%
Real Estate (VNQ)5.8%20.7%0.2429.8%
Bitcoin (BTCUSD)57.1%66.3%0.9712.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity3.6 Mil
Short Interest: % Change Since 101520265.0%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest6.3 days
Basic Shares Quantity45.5 Mil
Short % of Basic Shares7.9%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-2.6%-5.4% 
8/6/20261.7%9.3%23.0%
5/7/20263.2%8.2%35.3%
2/5/2026-1.4%-12.8%-2.8%
11/6/202532.3%44.2%64.1%
8/7/2025-26.6%-28.9%-28.2%
5/8/20255.9%6.8%9.7%
2/6/2025-11.6%-13.9%-3.6%
...
SUMMARY STATS   
# Positive141416
# Negative11118
Median Positive6.6%8.7%10.0%
Median Negative-6.8%-7.6%-9.4%
Max Positive32.3%44.2%64.1%
Max Negative-26.6%-28.9%-28.2%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-2.6%-5.4% 
8/6/20261.7%9.3%23.0%
5/7/20263.2%8.2%35.3%
2/5/2026-1.4%-12.8%-2.8%
11/6/202532.3%44.2%64.1%
8/7/2025-26.6%-28.9%-28.2%
5/8/20255.9%6.8%9.7%
2/6/2025-11.6%-13.9%-3.6%
11/7/202410.7%17.4%3.9%
8/8/2024-10.8%-14.6%-14.6%
5/9/2024-0.7%3.5%-8.2%
2/8/20241.3%-7.6%3.2%
11/2/2023-1.1%-0.3%-2.5%
8/8/20231.5%4.7%0.1%
5/11/20233.3%2.9%6.1%
2/7/2023-5.9%-7.0%-10.5%
11/7/20223.6%-1.7%4.3%
8/10/20228.9%12.9%11.6%
5/10/202210.4%16.9%33.1%
2/8/202216.2%23.8%26.5%
11/9/2021-15.4%-18.6%-22.0%
8/11/20217.3%2.6%13.7%
5/13/2021-13.4%-5.5%0.4%
2/2/202113.0%21.3%6.3%
11/4/2020-6.8%7.0%10.4%
SUMMARY STATS   
# Positive141416
# Negative11118
Median Positive6.6%8.7%10.0%
Median Negative-6.8%-7.6%-9.4%
Max Positive32.3%44.2%64.1%
Max Negative-26.6%-28.9%-28.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/20/202610-K
12/31/202502/05/202610-Q
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/21/202510-K
12/31/202402/06/202510-Q
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/20/202410-K
12/31/202302/08/202410-Q
09/30/202311/02/202310-Q
06/30/202308/08/202310-Q
03/31/202305/22/202310-K
12/31/202202/07/202310-Q
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/20/202610-K
12/31/202502/05/202610-Q
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/21/202510-K
12/31/202402/06/202510-Q
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/20/202410-K
12/31/202302/08/202410-Q
09/30/202311/02/202310-Q
06/30/202308/08/202310-Q
03/31/202305/22/202310-K
12/31/202202/07/202310-Q
09/30/202211/08/202210-Q
06/30/202208/10/202210-Q
03/31/202205/25/202210-K
12/31/202102/08/202210-Q
09/30/202111/09/202110-Q
06/30/202108/11/202110-Q
03/31/202105/26/202110-K
12/31/202002/02/202110-Q
09/30/202011/04/202010-Q
06/30/202008/04/202010-Q
03/31/202005/20/202010-K
12/31/201902/04/202010-Q

Recent Forward Guidance

Updated 11/6/2026

Latest: Q2 2027 Earnings Reported 11/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2027 53rd Week ImpactReported -0.02    
2027 Strategic Exits ImpactReported 0.01    
2027 Currency ImpactReported00.010.01   
2027 Reported Revenue GrowthReported8.0%9.5%11.0% 3.0%RaisedGuidance: 6.5% for 2027
2027 Organic Revenue GrowthReported6.0%7.5%9.0% 2.0%RaisedGuidance: 5.5% for 2027
2027 Adjusted Operating Margin ExpansionReported0.0%0.25%0.5%   
2027 Free Cash Flow ConversionReported0.80.8  0.0%AffirmedGuidance: 0.8 for 2027


Prior: Q1 2027 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2027 Reported Revenue GrowthReported5.0%6.5%8.0% 1.0%RaisedGuidance: 5.5% for 2027
2027 Organic Revenue GrowthReported4.0%5.5%7.0% 1.0%RaisedGuidance: 4.5% for 2027
2027 Free Cash Flow ConversionReported 0.8  0.0%AffirmedGuidance: 0.8 for 2027

Q4 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2027 Reported Revenue GrowthReported4.0%5.5%7.0%   
2027 Organic Revenue GrowthReported3.0%4.5%6.0%   
2027 Adjusted Operating Margin ChangeReported0.5%0.75%1.0%   
2027 Free Cash Flow ConversionReported 0.8    

Q3 2026 Earnings Reported 2/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Adjusted Operating MarginReported26.0%26.5%27.0% 0.0%AffirmedGuidance: 26.5% for 2026
2026 Free Cash Flow to Adjusted Net IncomeReported 0.8    
2026 Adjusted EPSReported4.94.9551.0% RaisedGuidance: 4.9 for 2026
2026 Free Cash FlowReported200.00 Mil210.00 Mil220.00 Mil10.5% RaisedGuidance: 190.00 Mil for 2026

Insider Activity

Updated 11/13/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Maunsell, Farris MaryanneVP, Chief Accounting OfficerDirectSell11132026120.99836101,148705,130Form
2Kroll, Mark W DirectBuy1112202570.561,40098,7841,746,854Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Maunsell, Farris MaryanneVP, Chief Accounting OfficerDirectSell11132026120.99836101,148705,130Form
2Kroll, Mark W DirectBuy1112202570.561,40098,7841,746,854Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
North Peak Capital Management, LLC$56.3 Mil9.4%7TRIM -9.4%13F
Silverback Asset Management LLC$13.6 Mil2.7%45New13F
Opti Capital Management, LP$11.9 Mil0.9%36New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Silverback Asset Management LLC$13.6 Mil2.7%45New13F
Opti Capital Management, LP$11.9 Mil0.9%36New13F
Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
Angelo Gordon & Co., L.P.$5.9 Mil0.6%46ExitedDec 31, 202513F
North Peak Capital Management, LLC$56.3 Mil9.4%7TRIM -9.4%Mar 31, 202613F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
North Peak Capital Management, LLC$56.3 Mil9.4%7TRIM -9.4%13F
Silverback Asset Management LLC$13.6 Mil2.7%45New13F
Opti Capital Management, LP$11.9 Mil0.9%36New13F
Core Cache Last Updated: 11/18/2026